Women at high risk of breast cancer find novel decision-aid tool helpful, pilot study shows

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A decision-making aid to help women at high risk of breast cancer decide whether to add MRIs to their screening regimen has proved popular with both patients and doctors alike in early testing.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents


Positive high-level results from the DESTINY-Breast06 phase III trial showed that Enhertu (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in the primary trial population of patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer following one or more lines of endocrine therapy.